Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Laryngopharyngeal Reflux

ClinicalTrials.gov lists 74 trials for Laryngopharyngeal Reflux or a narrower condition beneath it.

MeSH D057045 Digestive System Diseases C06 C08
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 3 Phase 2 Phase 2 2 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 2 Phase 4 Phase 4 12 Not applicable Not applicable 34 Observational Observational 20 Phase 1 Phase 1 3 Phase 2 Phase 2 2 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 2 Phase 4 Phase 4 12 Not applicable Not applicable 34 Observational Observational 20

Trials per phase (log scale)

53 of the 74 trials are tagged with Laryngopharyngeal Reflux itself; the rest are tagged with a narrower condition beneath it.

Get the Laryngopharyngeal Reflux report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Laryngopharyngeal Reflux trials start? (23)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 8

2001: 1 trials (Phase 4 1) 2003: 1 trials (Phase 2/3 1) 2004: 1 trials (Not applicable 1) 2005: 3 trials (Not applicable 2, Phase 1 1) 2006: 2 trials (Observational 1, Phase 4 1) 2009: 2 trials (Phase 3 1, Phase 1 1) 2010: 2 trials (Phase 4 2) 2011: 4 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1) 2012: 7 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 2 1) 2013: 5 trials (Observational 1, Not applicable 3, Phase 4 1) 2014: 1 trials (Phase 4 1) 2015: 1 trials (Not applicable 1) 2016: 3 trials (Observational 1, Not applicable 1, Phase 4 1) 2017: 1 trials (Not applicable 1) 2018: 5 trials (Observational 2, Not applicable 3) 2019: 5 trials (Observational 1, Not applicable 4) 2020: 2 trials (Observational 1, Not applicable 1) 2021: 8 trials (Observational 1, Not applicable 6, Phase 1 1) 2022: 3 trials (Observational 2, Not applicable 1) 2023: 6 trials (Observational 3, Not applicable 2, Phase 4 1) 2024: 3 trials (Observational 3) 2025: 4 trials (Observational 2, Not applicable 1, Phase 4 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 3
2025 4
2024 3
2023 6
2022 3
2021 8
2020 2
2019 5
2018 5
2017 1

No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 48 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Laryngopharyngeal Reflux trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 3
Phase 2 2
Phase 2/3 1
Phase 3 2
Phase 4 12
Not applicable 34
Observational 20

How many Laryngopharyngeal Reflux trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 5
Enrolling by invitation 2
Active, not recruiting 1
Completed 45

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Laryngopharyngeal Reflux trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Nutricia Research 2
Takeda 2
Ascension Health 1
AstraZeneca 1

Which drugs are being tested for Laryngopharyngeal Reflux? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Omeprazole 20 mg 5
E3810 1

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexlansoprazole MR 3
lansoprazole OD 3
Nexium Pill 2
Dexlansoprazole MR QD 1
Ranitidine hydrochloride ODT 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Laryngopharyngeal Reflux trials report? (8)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Animal bite 1 1
Breast cancer female 1 1
Cellulitis 1 1
Diverticular perforation 1 1
Dizziness 1 1

Which publications cover Laryngopharyngeal Reflux? (70)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Changes of Pepsin Concentration in Saliva Sample According to Storage Period. Journal of voice : official journal of the Voice Foundation 2025 Yes
Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2024 Yes
Esophageal Hypervigilance and Visceral Anxiety Contribute to Symptom Severity of Laryngopharyngeal Reflux. The American journal of gastroenterology 2023 Yes
Upper Esophageal Sphincter Compression Device as an Adjunct to Proton Pump Inhibition for Laryngopharyngeal Reflux. Digestive diseases and sciences 2022 Yes
Anatomical and physiological characteristics in patients with Laryngopharyngeal Reflux Symptoms: A case-control study utilizing high-resolution impedance manometry. Journal of the Formosan Medical Association = Taiwan yi zhi 2022 Yes

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages